Protocol Ledger

NCT06238622 · Phase III · ACTIVE NOT RECRUITING

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Interventional Phase III clinical trial protocol NCT06238622 sponsored by Boehringer Ingelheim in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-26 Enrollment: 1,666 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06238622
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,666 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06238622
Protocol FieldVerified Registry Value
NCT IdentifierNCT06238622
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment1,666 participants (ACTUAL)
Registered Start Date2024-09-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI